EpilepsyGTx has closed a £24.8m collection A spherical to advance the event of its single dose gene remedy for focal refractory epilepsy.
The funding will allow the supply of first-in-human section 1/2a medical trials to ascertain the security and efficacy of the corporate’s lead gene remedy programme EPY201 in a broad inhabitants of sufferers with focal refractory epilepsy (FRE).
Focal epilepsy describes a bunch of problems during which sufferers expertise seizures that come up from a particular a part of the mind. If seizures persist regardless of trials of no less than two tolerated and appropriately chosen anti-seizure medicines, epilepsy is deemed refractory. FRE impacts about ten million sufferers worldwide.
EPY201 presents the potential to eradicate seizures in sufferers with FRE with a single intervention, dramatically enhancing survival and high quality of life.
“Refractory epilepsy is a devastating situation inflicting unpredictable and life-threatening seizures, affecting thousands and thousands of sufferers worldwide,” says Nicolas Koebel, CEO at EpilepsyGTx.
“Our novel gene remedy EPY201 delivered on to the seizure focus has the potential to cease seizures with a single, minimally invasive administration. In doing so, it would change the best way refractory epilepsy has been handled for many years.”
The spherical included funding from XGEN Enterprise, the British Enterprise Financial institution and a world biopharmaceutical firm.
“EpilepsyGTx is pioneering a novel, domestically administered gene remedy strategy designed to realize focused modulation of epileptogenic mind areas,” provides Federica Draghi, managing associate of XGEN Enterprise.
“We imagine that localised gene supply presents a robust avenue for sturdy and disease-modifying interventions in extreme neurological problems and are excited to assist the corporate as EPY201 progresses towards medical analysis.”
EpilepsyGTx beforehand raised £7.5m in pre-seed and seed funding led by the UCL Know-how Fund.
